Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

A gene therapy carrier and medicine for retinitis pigmentosa

A vector and viral vector technology, applied in the field of genetic engineering, can solve the problems of low expression efficiency, short duration, cytotoxicity, etc., achieve stable expression, and relieve the effects of retinitis pigmentosa

Active Publication Date: 2020-09-22
沈阳伟景生物科技有限公司
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, some studies have pointed out that there are still many problems in the use of recombinant viruses to deliver expression vectors to the eye and express therapeutic gene products in the eye, such as low expression efficiency, short duration, and potential cytotoxicity.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A gene therapy carrier and medicine for retinitis pigmentosa
  • A gene therapy carrier and medicine for retinitis pigmentosa
  • A gene therapy carrier and medicine for retinitis pigmentosa

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0057] Embodiment 1, construction and isolation and purification of viral vector

[0058] The plasmid packaged into AAV2 was named pTR-sCBA-AT2R Intron 1-hPDE6b. The construction method of pTR-sCBA-AT2RIntron 1-hPDE6b is as follows figure 1 , figure 2As shown, the cDNA (SEQ ID NO: 1) of human PDE6b (hPDE6b) was cloned into the downstream of the sCBA (shortened chicken beta actin) promoter, and the plasmid also included pTR-sCBA-AT2R Intron 1-hPDE6b IE enhancer ( SEQ ID NO: 5) and the specific rat angiotensin II receptor intron 1 (Rat AT2R Intron 1, SEQ ID NO: 2), both of which can enhance the long-term expression of the transgene PDE6b. The hPDE6b cDNA is followed by the SV40 polyadenylation signal (SEQ ID NO:7) and the expression cassette is flanked by inverted terminal repeats, TR. Viral vectors also include ITR5' (SEQ ID NO:8), ITR3' (SEQ ID NO:9), ColE1ori (SEQ ID NO:10), Amp(r) (SEQ ID NO:11) and f1(+) origin (SEQ ID NO: 12).

[0059] The characteristic map of the v...

Embodiment 2

[0061] Example 2, Rat AT2R Intron 1 enhances the expression level of hPDE6b mRNA

[0062] 1. Experimental method

[0063] AAV2-sCBA-hPDE6b with Rat AT2R Intron 1 and AAV2-sCBA-hPDE6b without Rat AT2R Intron 1 were injected into the right and left eyes of the same 14-day-old rd10 mouse. One month later, the eyes were removed for detection mRNA expression levels of hPDE6b.

[0064] 2. Results

[0065] Compared with the traditional vector without Rat AT2R Intron 1, the AAV2-sCBA-hPDE6b viral vector with Rat AT2R Intron 1 (namely AAV2-sCBA-AT2RIntron 1-hPDE6b) can more than double the hPDE6b mRNA level in the injected eyes. ( image 3 )

Embodiment 3

[0066] Embodiment 3, the effect of AAV2-sCBA-AT2R Intron 1-hPDE6b virus vector injection on eye electroretinogram (rod cell ERG)

[0067] 1. Experimental method

[0068] Electroretinogram (ERG) was detected at different time points after subretinal injection of mice. Dark adaptation was carried out overnight. In order to eliminate the influence of detection at different times on the ERG amplitude, the detection was all set in the afternoon and operated under dark red light (>650nm) in a dark room. The mice were placed on a constant temperature platform at 37°C, a drop of compound tropicamide eye drops was instilled on the ocular surface, and then general anesthesia was performed, and the whiskers were cut off. Insert the reference electrode and the ground electrode under the skin of the head and the base of the tail, place a pair of gold ring electrodes on the surface of the cornea, drop a small amount of 2.5% hydroxymethylcellulose eye drops on the surface of the cornea to p...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to an adeno-associated virus vector. The adeno-associated virus vector can be used for treating or preventing retinal pigment degeneration caused by gene mutation of phosphodiesterase beta subunit (PDE6b). The adeno-associated virus vector provided by the invention includes a nucleic acid sequence and a promoter of the encoded phosphodiesterase beta subunit and an angiotensin type II receptor intron 1 capable of enhancing gene expression. The invention further relates to a medicine and a composition, which include the gene therapy vector.

Description

technical field [0001] The invention belongs to the technical field of genetic engineering, and more specifically, the invention relates to a gene therapy carrier and related drugs for retinitis pigmentosa. Background technique [0002] Retinitis pigmentosa is a severe blinding eye disease characterized by degeneration and apoptosis of retinal photoreceptor cells. Traditional medical methods have no effect on hereditary retinal diseases, so so far these diseases are still in a state of no cure. In recent years, with the development of genetic detection technology, it is known that such recessive retinal genetic diseases are caused by the loss of corresponding functional proteins caused by gene mutations. [0003] A severe subtype common in humans with autosomal recessive retinitis pigmentosa is due to mutations in the rod phosphodiesterase beta subunit (PDE6b) gene. The retinal cells contain a light-sensitive substance called rhodopsin. When it encounters light, its struc...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C12N15/864A61K48/00A61P27/02
CPCA61K38/465A61K48/005C12N15/86C12N2750/14143C12Y301/04001
Inventor 庞继景
Owner 沈阳伟景生物科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com